Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

862 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-09-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Blood clots in leg veins (deep vein thrombosis) or lung arteries (pulmonary embolism) that happen for no reason (i.e. unexplained) are both called "unprovoked venous thromboembolism" (VTE). These unexplained blood clots can be the first symptom of cancer. Up to 10% of patients with unexplained blood clots will be diagnosed with cancer within one year of their blood clot diagnosis.

These cancers can be found anywhere in the body although the relationship appears stronger with the pancreas, ovary and liver. Cancer testing in patients with blood clots is controversial. There is presently a wide variety of expert opinions and practices. Previous studies showed that a limited cancer screen including a medical history, physical examination, basic blood work and chest X-ray, will find about 90% of cancers. More recent and better designed studies showed that the limited cancer screen misses many cancers and needs to be improved. More extensive cancer testing may find more cancers but is potentially uncomfortable for patients, costs a lot of money and involves a lot of people.

The "comprehensive computed tomography" is less uncomfortable, inexpensive, radiological test made to find many cancers at once. Thus, the scientific question to be asked is: Does a "comprehensive computed tomography" miss less cancers than a limited cancer screen in patients with blood clots?

The main goal of this study is to find out if a "comprehensive computed tomography" misses less cancers than a limited cancer screen in patients with unexplained blood clots.

The second goal of the study is 1) to find out if a "comprehensive computed tomography" finds more "curable" cancers than the limited cancer screen; 2) to find out if the patients diagnosed with cancer are still alive and cancer-free after one year (i.e. the patients with curable cancer were treated and are doing well); 3) to prove that a negative "comprehensive computed tomography" means that the patient will not have cancer and; 4) to find out if a "comprehensive computed tomography" is well tolerated and safe for patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Screening for Occult Malignancy in Patients with Unprovoked Venous Thromboembolism

NCT04304651

Embolism and Thrombosis

RECRUITING NA

Screening for Occult Malignancy in Idiopathic Venous Thromboembolism

NCT00361647

Venous Thromboembolism

COMPLETED NA

Assessing the Prognosis of Pulmonary Embolism Using Clinical and Imaging Biomarkers (Retrospective & Prospective )

NCT00805246

Pulmonary Embolism

COMPLETED

Molecular Imaging of Active Venous Thrombus With Positron Emission Tomography (PET)

NCT06057844

Venous Thromboembolism (VTE)

RECRUITING NA

Cancer-related Venous Thromboembolic Disease - Cohort Study

NCT06393764

Thrombosis Embolism Thromboses, Venous Cancer

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism Deep Vein Thrombosis Pulmonary Embolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Limited Malignancy Screening

Group Type ACTIVE_COMPARATOR

Limited Malignancy Screening

Intervention Type OTHER

1\) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)

In women, a pap smear/pelvic examination (if \> 18 and \< 70 years old and not performed during the past year),a mammogram (\> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (\>40 years old) will be performed if not conducted in the past year.

Extensive Malignancy Screening

Limited screen as described above in combination with comprehensive computed tomography of the abdomen/pelvis

Group Type EXPERIMENTAL

Comprehensive computed tomography of the abdomen/pelvis

Intervention Type DEVICE

Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Comprehensive computed tomography of the abdomen/pelvis

Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.

Intervention Type DEVICE

Limited Malignancy Screening

1\) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)

In women, a pap smear/pelvic examination (if \> 18 and \< 70 years old and not performed during the past year),a mammogram (\> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (\>40 years old) will be performed if not conducted in the past year.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a new diagnosis of unprovoked proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) will be eligible to participate into the study:

* Unprovoked VTE is defined as the absence of any of the following predisposing factors:

1. known active cancer;
2. recent (less than 3 months) paralysis, paresis or plaster immobilization of the lower extremities;
3. recently bedridden for period of 3 or more days, or major surgery, within the previous 12 weeks requiring general or regional anaesthesia;
4. previous unprovoked VTE;
5. known thrombophilia (hereditary or acquired)
* Proximal DVT is defined as a non-compressibility of any vein segment from the common femoral vein to the trifurcation of the popliteal vein or a persistent intra-luminal filling defect of the iliac, common femoral, superficial femoral or popliteal veins on contrast venography.
* Pulmonary embolism is defined as:

1. patients with a high/intermediate pre-test probability (Wells' model \> 4) + high probability V/Q scan;
2. positive pulmonary angiogram; or
3. spiral CT demonstrating intraluminal filling defect in a vessel larger than a segmental artery

Exclusion Criteria

Patients will be excluded from the study if they have any of the following criteria:

* Age \< 18 years-old;
* Refusal or inability to provide informed consent;
* Greater than 21 days post diagnosis of idiopathic VTE
* Index VTE event of UEDVT or unusual site DVT
* Diagnosis of SSPE in the absence of above or below knee DVT
* Allergy to contrast media;
* Creatinine clearance \< 60 ml/min;
* Claustrophobia or agoraphobia;
* Weight \> 130 kg;
* Diagnosis of ulcerative colitis; and
* Diagnosis of glaucoma
* Current pregnancy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No